2026-06-17

Texas Permian Basin: drought conditions detected - potential oil supply impact

OSINT: US S&P 500 Index Slides 5%

Cotton bull 6.3% vs prior close ($75.01 → $79.73)

Platinum volume spike - 2.4× the 20-day average (31 vs 12 avg)

OSINT: US Oil Market Alert Signals Potential Supply Shift

OSINT: US and Iran Seal Agreement at Bürgenstock, Switzerland

OSINT: China Deploys New 155mm Naval Gun, Boosting Firepower Near Taiwan

Oil -6.69% - significant selloff

Platinum bear 4.1% vs prior close ($1,812.10 → $1,738.30)

Wheat bull 4.3% vs prior close ($596.00 → $621.50)

Gold -1.12% - significant selloff

Oil -1.13% - significant selloff

Gold +1.11% - significant rally

Oil +1.12% - significant rally

Oil -1.12% - significant selloff

OSINT: US COT Forecast Signals Dedollarization Trend in FX Markets

OSINT: Ukrainian Drone Strikes Gazprom Refinery Near Moscow

Sugar No. 11 bull 4.0% vs prior close ($13.82 → $14.37)

ETH ETF inflow of $139M - institutional buying

BTC ETF inflow of $1031M - institutional buying

BTC open interest +248.9% - OI surge

SOL open interest -62.5% - OI collapse

ETH open interest +225.5% - OI surge

ETH open interest -67.9% - OI collapse

SOL open interest -34.4% - OI collapse

BTC open interest +67.0% - OI surge

BTC open interest +102.6% - OI surge

ETH open interest -68.9% - OI collapse

SOL open interest -33.1% - OI collapse

SPYx/USDC has $67.6M volume but only $748K liquidity - thin market, slippage risk

SOL open interest -32.3% - OI collapse

ETH open interest -66.8% - OI collapse

BTC open interest -40.7% - OI collapse

OSINT: Large $HYPE Withdrawal by Wallet 0x6436 Sparks Sell Pressure

OSINT: CredibleFin partners OwlTing to launch stablecoin payments China‑India

OSINT: US COT Forecast Signals Dedollarization Trend in FX Markets

OSINT: On-chain products poised for mainstream app integration amid clearer regs

OSINT: Whale bets $1.8M against Argentina in World Cup opener

Phase 3 trial terminated early - JOHNSON Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Phase 3 trial terminated early - JOHNSON The Duration Study

Phase 3 trial terminated early - JOHNSON MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Au

Phase 3 trial terminated early - ELI Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adul

Phase 3 trial terminated early - BRISTOL A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone i

Phase 3 trial terminated early - BRISTOL Apixaban in Patients With Sickle Cell Disease

Phase 3 trial terminated early - BIOGEN A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progressi

Phase 3 trial terminated early - BIOGEN Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta

Phase 3 trial terminated early - BIOGEN Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

Phase 3 trial terminated early - AMGEN Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adul

Phase 3 trial terminated early - INCYTE A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Phase 3 trial terminated early - REGENERON Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia

Phase 3 trial terminated early - Medtronic Ligasure II: Standard Stapling Versus Ligasure

Phase 3 trial terminated early - Medtronic Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventr

Phase 3 trial terminated early - AbbVie A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endomet

Phase 3 trial terminated early - AbbVie UNITE Study: Understanding New Interventions With GBM ThErapy

Phase 3 trial terminated early - Merck Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian

Phase 3 trial terminated early - Merck Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Phase 3 trial terminated early - Merck Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (

Phase 3 trial terminated early - Merck LARC Forward Contraceptive Counseling at MHCC

Phase 3 trial terminated early - PFIZER Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic

Phase 3 trial terminated early - PFIZER A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In

Phase 3 trial terminated early - PFIZER Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Para

Phase 3 trial terminated early - PFIZER A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheime

Phase 3 trial terminated early - PFIZER Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy

Phase 3 trial terminated early - PFIZER An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dim

Phase 3 trial terminated early - ABBOTT The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Car

Phase 3 trial terminated early - ABBOTT Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheum

Phase 3 trial terminated early - ABBOTT Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's

Phase 3 trial terminated early - GILEAD Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropa

Phase 3 trial terminated early - GILEAD (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effect

Phase 3 trial terminated early - GILEAD Virtual PrEP: Rendering PrEP Delivery More Efficient

Phase 3 trial terminated early - GILEAD B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Activist 13D filing - tender offer

OSINT: USAF reports loss of E-4B and three KC-135 tankers in incident

Sanofi search volume spiked +77 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

Missed consensus by 42.4% - EPS $-318 vs $-223.38 estimate

Missed consensus by 322.0% - EPS $-361.6 vs $-85.68 estimate

Missed consensus by 114.9% - EPS $-4083 vs $-1900.26 estimate

Beat consensus by 98.8% - EPS $-1.8 vs $-149.94 estimate

Missed consensus by 175.4% - EPS $-0.6 vs $-0.2179 estimate

Beat consensus by 6.2% - EPS $-0.25 vs $-0.2664 estimate

Missed consensus by 347.3% - EPS $-1.35 vs $-0.3018 estimate

Missed consensus by 17.6% - EPS $-43.2 vs $-36.72 estimate

Beat consensus by 17.0% - EPS $-28.8 vs $-34.68 estimate

Missed consensus by 23.0% - EPS $2.3 vs $2.987 estimate

Missed consensus by 19.7% - EPS $2.48 vs $3.09 estimate

Beat consensus by 8.7% - EPS $-0.163 vs $-0.1785 estimate

Missed consensus by 73.8% - EPS $-0.26 vs $-0.1496 estimate

Q1-2027: Beat consensus by 35.9% - EPS $1.31 vs $0.9638 estimate

Q1-2026: Beat consensus by 202.0% - EPS $1.91 vs $0.6324 estimate

Q1-2026: Beat consensus by 7.3% - EPS $-0.638 vs $-0.6885 estimate

Beat consensus by 94.7% - EPS $-0.01 vs $-0.1877 estimate

Beat consensus by 7.4% - EPS $0.938 vs $0.873 estimate

Beat consensus by 273.7% - EPS $3.43 vs $0.9178 estimate

Q1-2027: Beat consensus by 6.4% - EPS $-0.21 vs $-0.2244 estimate

Q2-2026: Beat consensus by 106.1% - EPS $0.01 vs $-0.1632 estimate

Q1-2026: Beat consensus by 19.2% - EPS $0.3 vs $0.2516 estimate

Beat consensus by 74.3% - EPS $1600 vs $918 estimate

Beat consensus by 24.8% - EPS $700 vs $561 estimate

Beat consensus by 142.0% - EPS $0.3 vs $-0.714 estimate

Beat consensus by 49.4% - EPS $-1.1 vs $-2.176 estimate

GE Vernova Inc. search volume spiked +100 pts - unusual interest

LINDE PLC search volume spiked +100 pts - unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

Sanofi search volume spiked +77 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

Q1-2026: Missed consensus by 34.6% - EPS $0.31 vs $0.4743 estimate

Q1-2027: Beat consensus by 70.3% - EPS $-0.02 vs $-0.0673 estimate

LINDE PLC search volume spiked +100 pts - unusual interest

GE Vernova Inc. search volume spiked +100 pts - unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

Sanofi search volume spiked +77 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

OSINT: CredibleFin partners OwlTing to launch stablecoin payments China‑India

LINDE PLC search volume spiked +100 pts - unusual interest

INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

GE Vernova Inc. search volume spiked +100 pts - unusual interest

Sanofi search volume spiked +77 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

Strategy Inc search volume spiked +26 pts - unusual interest

OSINT: On-chain products poised for mainstream app integration amid clearer regs

Q1-2026: EPS $0.002 vs $-0.0103 estimate, +0.01 on a near-zero consensus

Q4-2025: EPS $0.01 vs $-0.0408 estimate, +0.05 on a near-zero consensus

Q4-2025: EPS $0.07 vs $0.0281 estimate, +0.04 on a near-zero consensus

Q2-2026: EPS $0.01 vs $0.0306 estimate, -0.02 on a near-zero consensus

EPS $0.08 vs $-0.0092 estimate, +0.09 on a near-zero consensus

Q1-2026: EPS $-0.03 vs $0.0051 estimate, -0.04 on a near-zero consensus

Q2-2026: EPS $0.01 vs $-0.0278 estimate, +0.04 on a near-zero consensus

OSINT: USAF reports loss of E-4B and three KC-135 tankers in incident

VIX at 18.4 - CAUTION territory

OSINT: Hegseth's actions spark US ally backlash over renaming initiatives

OSINT: Ukrainian Drone Strikes Gazprom Refinery Near Moscow

Financial conditions loosening - NFCI at -0.51, liquidity supportive

OSINT: US Housing Starts Plunge 15.4% MoM in May, Lowest Since 2020

DXY RSI 71.8 - overbought (crossed above 70)

DXY +0.46% - dollar strength signal

OSINT: CredibleFin partners OwlTing to launch stablecoin payments China‑India

OSINT: US COT Forecast Signals Dedollarization Trend in FX Markets

OSINT: Hegseth's actions spark US ally backlash over renaming initiatives

OSINT: Ukrainian Drone Strikes Gazprom Refinery Near Moscow

OSINT: US Median Home Price Hits $395K in May, Highest in Years

OSINT: Whale bets $1.8M against Argentina in World Cup opener